Switzerland has become a global leader in cutting-edge cancer research, with close collaborations between research institutions, hospitals, and private industry fostering the next generation of globally impactful cancer innovation. …
As global trade tensions escalate, Switzerland’s export-driven pharmaceutical industry finds itself at a challenging moment. In May 2025, the United States imposed tariffs of up to 39 percent on Swiss…
In an uncertain world, Europe – with Switzerland at its heart – is reclaiming its role as an epicentre for testing, scaling, and integrating new medical technologies. While much…
Manufacturing – long sidelined as a relatively prosaic element of the global pharma supply chain – is back in the news. Investment in manufacturing facilities is skyrocketing as sponsors rush…
Switzerland stands among the world’s leading pharmaceutical manufacturing and export hubs; though that position now faces headwinds from recent US policy moves, as detailed elsewhere in this report. Yet making…
With the Trump administration imposing tariffs of up to 39 percent on Swiss goods (recently reduced to 15 percent), the pressure on Switzerland’s most influential industrial sector – pharmaceuticals –…
For a tiny Alpine nation nestled deep in the interior of continental Europe, Switzerland boasts a spectacularly vibrant biotech scene. This is because “the country manages to leverage its compact…
Helsinn has recently entered one of the most consequential transformations in its history. As it prepares for a new transition at the helm of the company, Executive Chairman Riccardo Braglia…
Global pharma is rushing to relocate manufacturing to the US. To reduce dependence on foreign manufacturing sources – most notably from its main economic adversary, China – the Trump administration…
Drawn from Healthcare & Life Sciences Review Denmark 2025, this selection captures the major forces now reshaping one of Europe’s most dynamic life science hubs. From Denmark’s bid to double…
First published in the September/October 2025 edition of ISPOR’s Value & Outcomes Spotlight, David Thompson (Rubidoux Research), Christopher Blanchette (Clinical, Medical and Regulatory Affairs), and Stephanie Earnshaw (Access Strategy Consulting)…
First published in the November 2025 issue of DIA’s Global Forum, this article by Victoria Gamermanusa (RWD Insights) tackles one of rare disease research’s toughest dilemmas: how to run credible…
See our Cookie Privacy Policy Here
